Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: February 23, 2006
Last updated: January 3, 2014
Last verified: April 2007

RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after transplant may stop this from happening.

PURPOSE: This clinical trial is studying how well a donor stem cell transplant works in treating patients with hematologic cancer, metastatic kidney cancer, or aplastic anemia.

Condition Intervention
Chronic Myeloproliferative Disorders
Kidney Cancer
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Biological: anti-thymocyte globulin
Biological: filgrastim
Biological: graft-versus-tumor induction therapy
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment: 35
Study Start Date: May 2005
Detailed Description:



  • Determine the treatment-related mortality (TRM) rate at 100 days in patients with hematologic malignancy, metastatic renal cell carcinoma, or aplastic anemia undergoing nonmyeloablative allogeneic stem cell transplantation using matched unrelated donors.


  • Determine the TRM at 12 months in patients treated with this regimen.
  • Determine the 6-month engraftment rate in patients treated with this regimen.
  • Determine 1-year overall survival of patients treated with this regimen.


  • Nonmyeloablative preparative regimen: Patients receive fludarabine IV over 30 minutes on days -7 to -3, busulfan* IV over 6 hours on days -4 and -3, and anti-thymocyte globulin IV over 6-10 hours on days -4 to -1.

NOTE: *Patients with aplastic anemia receive cyclophosphamide IV over 2 hours on days -6 to -3 instead of busulfan.

  • Allogeneic stem cell reinfusion: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 7 and continuing until blood counts recover.
  • Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus orally twice daily or IV continuously beginning on day -2 and continuing for approximately for 6-12 months after transplantation. Patients also receive mycophenolate mofetil orally or IV twice daily on days 0 to 60 and methotrexate IV on days 1, 3, 6, and 11**.

NOTE: **Patients with aplastic anemia receive methotrexate IV on days 1, 3, and 6 (not day 11).

  • Donor lymphocyte infusion (DLI): After day 180, patients with no evidence of active GVHD may receive DLI. A second DLI may be infused > 8 weeks after the first in the absence of disease response or GVHD.

After completion of study treatment, patients are followed periodically for at least 2 years.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.


Ages Eligible for Study:   up to 74 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following:

    • Aplastic anemia not responsive to immunosuppressive therapy
    • Metastatic renal cell carcinoma
    • Hematologic malignancy, including any of the following:

      • Acute myeloid leukemia (AML)* not curable with chemotherapy and meeting any of the following criteria:

        • AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive [Ph+])
        • AML evolved from prior myelodysplasia
        • AML secondary to prior chemotherapy
        • Failed to achieve remission
        • In second or subsequent remission NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy
      • Myelodysplasia* with any of the following high-risk features:

        • Adverse cytogenetics (-7, 7q, -5, -5q, complex)
        • Excess blasts
        • Prior conversion to AML
        • Severe cytopenias with absolute neutrophil count < 500/mm^3 or platelet count < 20,000/mm^3 NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy
      • Acute lymphoblastic leukemia (ALL)* not curable with chemotherapy and meeting any of the following criteria:

        • High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7)
        • More than 1 induction course required to achieve remission
        • Failed to enter remission
        • In second or subsequent remission NOTE: *Marrow blasts < 10 %
      • Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following:

        • Refractory to initial or subsequent therapy
        • Progression after initial response to therapy
        • Prolymphocytic morphology
      • Follicular lymphoma with any of the following high-risk features:

        • Refractory to initial or subsequent therapy
        • Progression after response to initial therapy
        • Has ≥ 3 International Prognostic Index (IPI) risk factors
      • Multiple myeloma

        • Stage II-III disease confirmed at diagnosis or after initial progression
      • Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following:

        • Diffuse large cell lymphoma
        • Mantle cell lymphoma
        • Hodgkin's lymphoma
      • Myeloproliferative disease with evidence of disease acceleration, including any of the following:

        • Myelofibrosis
        • Polycythemia vera
        • Essential thrombocythemia
      • Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate
  • Disease must be stable or responding to therapy
  • No rapid progression of malignant disease

    • Expected time to disease progression > 12 weeks
  • Not eligible for autologous stem cell transplantation
  • Matched unrelated donor available

    • 9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ


  • Creatinine < 2.0 mg/dL
  • Creatinine clearance > 40 mL/min
  • Bilirubin < 3 mg/dL

    • Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal
  • AST < 4 times upper limit of normal
  • Hepatitis C or B allowed provided bilirubin and AST are normal
  • Cardiac ejection fraction > 30%
  • DLCO > 40% of predicted
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No uncontrolled active infection requiring ongoing antibiotic treatment
  • No poor performance status
  • No poor organ function


  • See Disease Characteristics
  • Prior stem cell or bone marrow transplantation allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00295997

United States, California
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, North Carolina
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Principal Investigator: Charles A. Linker, MD University of California, San Francisco
  More Information Identifier: NCT00295997     History of Changes
Other Study ID Numbers: CDR0000463522
Study First Received: February 23, 2006
Last Updated: January 3, 2014

Keywords provided by National Cancer Institute (NCI):
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
accelerated phase chronic myelogenous leukemia
adult acute lymphoblastic leukemia in remission
adult acute myeloid leukemia in remission
atypical chronic myeloid leukemia, BCR-ABL1 negative
blastic phase chronic myelogenous leukemia
childhood acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood chronic myelogenous leukemia
chronic eosinophilic leukemia
primary myelofibrosis
chronic myelomonocytic leukemia
chronic neutrophilic leukemia
chronic phase chronic myelogenous leukemia
de novo myelodysplastic syndromes
essential thrombocythemia
juvenile myelomonocytic leukemia
myelodysplastic/myeloproliferative neoplasm, unclassifiable
polycythemia vera
previously treated myelodysplastic syndromes
recurrent adult acute myeloid leukemia
prolymphocytic leukemia
recurrent adult Hodgkin lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent/refractory childhood Hodgkin lymphoma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Kidney Neoplasms
Carcinoma, Renal Cell
Anemia, Aplastic
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions processed this record on May 25, 2017